News | Radiation Therapy | October 07, 2016

Philips Unveils Advanced Radiation Oncology Imaging, Treatment Planning Innovations at ASTRO 2016

Company highlights latest version of CT Big Bore, Pinnacle3 treatment planning software and Ingenia MR-guided radiotherapy

Philips Healthcare, ASTRO 2016, radiation therapy, CT Big Bore, Ingenia MR-RT, Pinnacle treatment planning

October 7, 2016 — Philips Healthcare featured its latest integrated imaging and treatment planning solutions for radiation oncology at the American Society for Therapeutic Radiology and Oncology’s (ASTRO) 58th Annual Meeting, Sept. 25-28 in Boston. Designed to fit the unique needs of radiation oncology clinicians and patients, these solutions have been developed to put more control in the hands of the clinician, with the intent to improve workflow and operational efficiencies, drive procedure accuracy and ultimately improve care.

Over the past few years, cancer care has evolved to deliver more advanced treatments and technologies that do not always integrate seamlessly. For example, the treatment plan plays a big role in determining the quality of the treatment itself. For most patients, this means waiting for a week or more after their simulation scan to start their treatment, which can lead to increased anxiety. According to the National Cancer Institute, in many cases, this not only affects a patient’s ability to cope with treatment, but also impacts their quality of life. As technology and treatments for cancer advance, the patient experience remains first and foremost. 

The Philips booth at ASTRO 2016 showcased the company’s advanced solutions enhancing its integrated radiation oncology approach with a full suite to help clinicians deliver quality cancer care to improve both the patient and staff experience.

Meeting offerings included the following:

  • CT Big Bore v4.2 with Tumor LOC and iPatient Platform – A computed tomography (CT) simulation solution designed for every cancer patient, delivering accuracy, reliability and an efficient workflow to drive clinical confidence in cancer treatment. Now integrated with both Philips’ Tumor LOC technology and iPatient Platform, Big Bore offers more powerful simulation and advanced marking tools to help speed time to treatment.    Powered by Pinnacle3, TumorLOC integrates scanning and planning to simplify and accelerate patient marking and CT simulation at the scanner console. Philips’ iPatient platform provides consistent image quality from scan-to-scan through patient-centered workflows for both routine and advanced 4-D imaging applications, making patient setup fast and easy.
  • Ingenia MR-RT – a dedicated magnetic resonance (MR) simulation platform providing clinicians with high-quality MR images acquired in the treatment position to help visualize targets and critical structures, allowing them to design the best possible treatment plans. The MR-only simulation for prostate treatment planning was recently given 510(k) clearance by the U.S. Food and Drug Administration (FDA). At ASTRO, Philips also showcased developments in intelligent workflow automation, such as automated contouring on MR-only based datasets (a work in progress).
  • Pinnacle3  — Now with a new intuitive user interface, Pinnacle³ offers seamless integration that enhances planning efficiency and quality while making plan workflow faster and less iterative. Pinnacle3 intelligent automation simplifies and accelerates the intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) planning process. Smart automation tools enable the user to create plans with limited clinician intervention while reducing the dose variability of manual planning workflows.

For more information: www.usa.philips.com/healthcare

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.